Carlos H. Fernandez-Rojas
Montreal, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications
Key Insights on the Impact of Sacubitril-Valsartan in Canada, Despite Limitations of Registry Data.
Journal: CJC open
Published: July 22, 2026
The Prevalence, Healthcare Resource Utilization, and Clinical Characteristics of Individuals with Atherosclerotic Cardiovascular Disease in Manitoba.
Journal: CJC open
Published: February 21, 2026
Outcomes, Safety and Tolerability of Sacubitril-Valsartan over 3 years of Follow-up in Canadian Practice: Insights from the PARTHENON Registry.
Journal: CJC open
Published: July 21, 2025
Longitudinal Control of Lipid Levels in Patients With Premature Coronary Artery Disease.
Journal: JACC. Advances
Published: May 12, 2023
Patient Eligibility for Established and Novel Guideline-Directed Medical Therapies After Acute Heart Failure Hospitalization.
Journal: JACC. Heart failure
Published: May 09, 2022
Optimal Usage of Sacubitril/Valsartan for the Treatment of Heart Failure: The Importance of Optimizing Heart Failure Care in Canada.
Journal: CJC open
Published: January 30, 2020
4β-Hydroxycholesterol as an Endogenous Biomarker for CYP3A Activity: Literature Review and Critical Evaluation.
Journal: Journal of clinical pharmacology
Published: December 28, 2018
CFH and ARMS2 Polymorphisms Interact with Zinc Supplements in Cognitive Impairment in the Women's Health Initiative Hormone Trial.
Journal: Journal of Alzheimer's disease : JAD
Published: October 16, 2018
Deprescribing recommendations: An essential consideration for clinical guideline developers.
Journal: Research in social & administrative pharmacy : RSAP
Published: August 28, 2018
Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline.
Journal: Canadian family physician Medecin de famille canadien
Published: January 24, 2018
Last Updated: 09/26/2026